{'fraction_non_alphanumeric': 0.03044496487119438, 'fraction_numerical': 0.0, 'mean_word_length': 5.294117647058823, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CAR T Cells: Hitting the Pause Button.

Researchers have shown, preclinically, that the small-molecule inhibitor dasatinib can temporarily halt the action of chimeric antigen receptor (CAR) T cells without compromising therapeutic efficacy. Dasatinib's effects are reversible upon drug removal, and the hope is that this strategy could be used to mitigate cytokine release syndrome, a serious side effect of CAR T-cell therapy.